Wpan-DSR Capsule PR is a combination pharmaceutical formulation containing Domperidone 30 mg and Pantoprazole 40 mg, designed for the management of gastrointestinal disorders. Domperidone is a peripheral dopamine D2 receptor antagonist that enhances gastrointestinal motility by increasing the tone and amplitude of gastric contractions, thereby facilitating gastric emptying and reducing symptoms of nausea and vomiting. Pantoprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The combination of these two agents offers a synergistic effect by addressing both delayed gastric emptying and excessive acid secretion, improving symptomatic relief and promoting mucosal healing. Wpan-DSR Capsule PR is indicated for patients experiencing upper gastrointestinal motility disorders accompanied by acid-related symptoms. It is generally well tolerated; however, it should be used with caution in patients with known hypersensitivity to either component or those with underlying cardiac conditions due to the potential risk of QT interval prolongation associated with Domperidone. Administration should follow medical advice, and dosage adjustments may be necessary based on clinical response and patient tolerance.